Metabolism - Clinical and Experimental
Volume 55, Issue 3 , Pages 345-352 , March 2006

Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome

Received 1 April 2005 ,Accepted 13 September 2005.

References 

  1. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, et al. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87:524–529
  2. Glueck CJ, Awadalla SG, Phillips H, et al. Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and miscarriage. Fertil Steril. 2000;74:394–397
  3. Glueck CJ, Wang P, Fontaine RN, et al. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism. 1999;48:1589–1595
  4. van der Spuy ZM, Dyer SJ. The pathogenesis of infertility and early pregnancy loss in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18:755–771
  5. Glueck CJ, Streicher P, Wang P. Treatment of polycystic ovary syndrome with insulin-lowering agents. Expert Opin Pharmacother. 2002;3:1177–1189
  6. Glueck CJ, Phillips H, Cameron D, et al. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril. 2001;75:46–52
  7. Glueck CJ, Wang P, Goldenberg N, et al. Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin. Clin Appl Thromb Hemost. 2004;10:323–334
  8. Glueck CJ, Phillips H, Cameron D, et al. The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: an independent risk factor for serious pregnancy complications. Metabolism. 2000;49:845–852
  9. Glueck CJ, Iyengar S, Goldenberg N, et al. Idiopathic intracranial hypertension: associations with coagulation disorders and polycystic-ovary syndrome. J Lab Clin Med. 2003;142:35–45
  10. Diamanti-Kandarakis E, Palioniko G, Alexandraki K, et al. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor–1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur J Endocrinol. 2004;150:793–798
  11. Glueck CJ, Wang P, Bornovali S, et al. Polycystic ovary syndrome, the G1691A factor V Leiden mutation, and plasminogen activator inhibitor activity: associations with recurrent pregnancy loss. Metabolism. 2003;52:1627–1632
  12. Sampson M, Kong C, Patel A, et al. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxf). 1996;45:623–629
  13. Buchholz T, Lohse P, Rogenhofer N, et al. Polymorphisms in the ACE and PAI-1 genes are associated with recurrent spontaneous miscarriages. Hum Reprod. 2003;18:2473–2477
  14. Dossenbach-Glaninger A, van Trotsenburg M, Dossenbach M, et al. Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss. Clin Chem. 2003;49:1081–1086
  15. Juhan-Vague I, Roul C, Alessi MC, et al. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients—relationship with plasma insulin. Thromb Haemost. 1989;61:370–373
  16. Glueck CJ, Wang P, Fontaine R, et al. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism. 1999;48:511–519
  17. Velazquez EM, Mendoza S, Hamer T, et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994;43:647–654
  18. Velazquez EM, Mendoza SG, Wang P, et al. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor–1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism. 1997;46:454–457
  19. Maly J, Mala H, Pecka M, et al. Changes of haemostasis in obese subjects during weight reduction, Vnitr Lek. 2001;47:203–209
  20. Aljada A, Garg R, Ghanim H, et al. Nuclear factor–kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action?. J Clin Endocrinol Metab. 2001;86:3250–3256
  21. Ghanim H, Garg R, Aljada A, et al. Suppression of nuclear factor–kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab. 2001;86:1306–1312
  22. Kruszynska YT, Yu JG, Olefsky JM, et al. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes. 2000;49:633–639
  23. Fonseca VA, Reynolds T, Hemphill D, et al. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non–insulin-dependent diabetes mellitus. J Diabetes Complications. 1998;12:181–186
  24. Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:2108–2116
  25. Gris JC, Ripart-Neveu S, Maugard C, et al. Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study. Thromb Haemost. 1997;77:1096–1103
  26. Gris JC, Neveu S, Mares P, et al. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology. J Lab Clin Med. 1993;122:606–615
  27. Glueck CJ, Bornovali S, Pranikoff J, et al. Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome. Diabet Med. 2004;21:829–836
  28. Vanky E, Salvesen KA, Heimstad R, et al. Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod. 2004;19:1734–1740
  29. Prisco D, Fatini C, Battaglini B, et al. Angiotensin converting enzyme DD genotype affects the changes of plasma plasminogen activator inhibitor–1 activity after primary percutaneous transluminal coronary angioplasty in acute myocardial infarction patients. Int J Clin Lab Res. 2000;30:179–185
  30. Kim DK, Kim JW, Kim S, et al. Polymorphism of angiotensin converting enzyme gene is associated with circulating levels of plasminogen activator inhibitor–1. Arterioscler Thromb Vasc Biol. 1997;17:3242–3247
  31. Dawson SJ, Wiman B, Hamsten A, et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor–1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 1993;268:10739–10745
  32. Brown NJ, Abbas A, Byrne D, et al. Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor–1 in healthy postmenopausal women. Circulation. 2002;105:304–309
  33. Ye S, Green FR, Scarabin PY, et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor–1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde. Thromb Haemost. 1995;74:837–841
  34. Lindahl B, Nilsson TK, Asplund K, et al. Intense nonpharmacological intervention in subjects with multiple cardiovascular risk factors: decreased fasting insulin levels but only a minor effect on plasma plasminogen activator inhibitor activity. Metabolism. 1998;47:384–390
  35. Cigolini M, Targher G, Seidell JC, et al. Relationships of plasminogen activator inhibitor–1 to anthropometry, serum insulin, triglycerides and adipose tissue fatty acids in healthy men. Atherosclerosis. 1994;106:139–147
  36. Henry M, Tregouet DA, Alessi MC, et al. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. Arterioscler Thromb Vasc Biol. 1998;18:84–91
  37. Byberg L, Siegbahn A, Berglund L, et al. Plasminogen activator inhibitor–1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men. Arterioscler Thromb Vasc Biol. 1998;18:258–264
  38. Marques-Vidal P, Sie P, Cambou JP, et al. Relationships of plasminogen activator inhibitor activity and lipoprotein(a) with insulin, testosterone, 17 beta-estradiol, and testosterone binding globulin in myocardial infarction patients and healthy controls. J Clin Endocrinol Metab. 1995;80:1794–1798
  39. Mykkanen L, Ronnemaa T, Marniemi J, et al. Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor–1 activity. Arterioscler Thromb. 1994;14:1264–1271
  40. Asplund-Carlson A, Hamsten A, Wiman B, et al. Relationship between plasma plasminogen activator inhibitor–1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia. 1993;36:817–825
  41. Vague P, Juhan-Vague I, Aillaud MF, et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism. 1986;35:250–253
  42. Tarkun I, Canturk Z, Arslan BC, et al. The plasminogen activator system in young and lean women with polycystic ovary syndrome. Endocr J. 2004;51:467–472
  43. Sobel BE. Increased plasminogen activator inhibitor–1 and vasculopathy. A reconcilable paradox. Circulation. 1999;99:2496–2498
  44. Dong J, Fujii S, Li H, et al. Interleukin-6 and mevastatin regulate plasminogen activator inhibitor–1 through CCAAT/enhancer-binding protein–{delta}. Arterioscler Thromb Vasc Biol. 2005;25:1078–1084
  45. Hu ZY, Liu YX, Liu K, et al. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta. J Anat. 1999;194(Pt 2):183–195
  46. Graham CH. Effect of transforming growth factor–beta on the plasminogen activator system in cultured first trimester human cytotrophoblasts. Placenta. 1997;18:137–143
  47. Group C. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–47
  48. Balasa VV, Gruppo RA, Glueck CJ, et al. The relationship of mutations in the MTHFR, prothrombin, and PAI-1 genes to plasma levels of homocysteine, prothrombin, and PAI-1 in children and adults. Thromb Haemost. 1999;81:739–744
  49. Glueck CJ, Freiberg RA, Fontaine RN, et al. Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop. 2001;386:19–33
  50. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419
  51. Glueck CJ, Goldenberg N, Wang P, et al. Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy. Hum Reprod. 2004;19:510–521
  52. Ieko M. Antiphospholipid antibodies and thrombosis: the putative mechanisms of hypercoagulable state in patients with anticardiolipin antibody, Rinsho Byori. 2000;48:293–300
  53. Kruithof EK, Tran-Thang C, Gudinchet A, et al. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood. 1987;69:460–466
  54. Moniwa N. Relationship of urokinase type plasminogen activator, plasminogen activator inhibitor type 1 and activated protein C in fibrinolysis of human placenta. Pol J Pharmacol. 1996;48:215–220

PII: S0026-0495(05)00365-3

doi: 10.1016/j.metabol.2005.09.008

Metabolism - Clinical and Experimental
Volume 55, Issue 3 , Pages 345-352 , March 2006

Article Tools

* Image Usage & Resolution